ArticleHealth economics review2026
Cost-utility analysis of three PD-1 inhibitors combined with chemotherapy in the first-line treatment of locally advanced or metastatic esophageal squamous carcinoma in China.
Article in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the economics of sintilimab combination chemotherapy versus chemotherapy and sintilimab combination chemotherapy versus camrelizumab/ toripalimab combination chemotherapy in the first-line treatment of locally advanced or metastatic esophageal squamous carcinoma (ESCC) from the perspective of the Chinese health system.
methodsA partitioned survival model (PSM) with a tracked time horizon of 5 years was developed. In the basal analysis, a direct cost-utility comparison of sintilimab + chemotherapy vs. chemotherapy in first-line treatment of advanced ESCC was performed based on survival data from the ORIENT-15 trial. Cost and utility value data were obtained from relevant databases or published literature, and the robustness of the model was assessed using one-way sensitivity analysis and probabilistic sensitivity analysis (PSA). In the exploratory analysis, the cost-utility of sintilimab + chemotherapy vs. camrelizumab/ toripalimab + chemotherapy was indirectly compared by Network Meta-Analysis (NMA) combined with hazard ratio (HR).
resultsSintilimab in combination with chemotherapy resulted in 0.33 quality-adjusted life years (QALYs) more than chemotherapy with an incremental cost-effectiveness ratio (ICER) of 25,409.27 USD/QALY, which was lower than the willingness-to-pay (WTP). Sensitivity analysis showed that the utility value of stable disease and the price of sintilimab had the greatest impact on outcome stability. Exploratory analysis indicate that toripalimab plus chemotherapy yields an additional 0.04 QALYs compared with sintilimab plus chemotherapy, with an ICER of 9,953.24 USD/QALY. In contrast, camrelizumab plus chemotherapy yields 0.05 fewer QALYs compared with sintilimab plus chemotherapy.
conclusionFor the first-line treatment of locally advanced or metastatic ESCC, the addition of sintilimab to conventional chemotherapy regimens was economical. Among similar PD-1 inhibitors, the toripalimab plus chemotherapy regimen is more costly but more effective than the sintilimab plus chemotherapy regimen, and is cost-effective at the WTP threshold of 3 × GDP per capita. In contrast, the camrelizumab plus chemotherapy regimen is dominated (higher cost and worse effectiveness) by the sintilimab plus chemotherapy regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.